A phase 2 trial of dasatinib in patients with lung adenocarcinoma with acquired resistance to erlotinib or gefitinib
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Dasatinib (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
- 30 Apr 2013 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
- 30 Apr 2013 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
- 09 Jul 2007 New trial record.